

# **Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), By Route of Administration (Injectable, Oral, Topical), By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy), By Region & Competition, 2021-2031F**

<https://marketpublishers.com/r/P0E8F528601BEN.html>

Date: January 2026

Pages: 185

Price: US\$ 4,500.00 (Single User License)

ID: P0E8F528601BEN

## **Abstracts**

The Global Peptide Antibiotics Market is projected to grow from USD 5.38 Billion in 2025 to USD 8.13 Billion by 2031, achieving a CAGR of 7.12%. These antibiotics are composed of short amino acid sequences that act as antimicrobial agents by disrupting bacterial membranes or interfering with vital intracellular processes. The market's growth is primarily fueled by the increasing global threat of antimicrobial resistance and the critical need for new treatments effective against multi-drug resistant infections. Unlike traditional small-molecule drugs, peptide antibiotics possess unique mechanisms of action and a reduced likelihood of inducing resistance, factors that are driving their expanded research and clinical adoption.

Despite this potential, market expansion faces significant hurdles regarding metabolic stability and the high costs associated with large-scale synthesis. The industry also contends with a weak developmental pipeline that restricts the availability of late-stage therapeutic options. For instance, the International Federation of Pharmaceutical Manufacturers and Associations reported in 2025 that the global clinical pipeline included only one antibiotic candidate in Phase III trials aimed at critical priority pathogens. This shortage of advanced candidates emphasizes the enduring economic

and scientific challenges that continue to impede the sector's progress.

### **Market Driver**

The rising global prevalence of antimicrobial resistance (AMR) serves as the primary driver for the Global Peptide Antibiotics Market. As bacterial pathogens develop defenses against standard small-molecule drugs, the demand for peptide-based therapeutics with unique modes of action has intensified. These agents are crucial for treating the increasing number of infections that fail to respond to first-line therapies. The World Health Organization's 'Global Antibiotic Resistance Surveillance Report 2025', released in October 2025, noted that resistance increased in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023. This trend highlights the urgent clinical need for peptides that disrupt bacterial membranes with a lower risk of resistance, while the WHO also reported in 2025 that one in six bacterial infections globally involved resistant pathogens, illustrating the vast market potential for these new interventions.

Concurrently, increased public and private funding for antibiotic R&D is accelerating market growth by alleviating the financial risks inherent in drug development. Although the high costs and limited commercial returns of antibiotic synthesis have historically stifled innovation, recent financial mechanisms have revitalized the industry. These investments allow biotechnology firms to progress early-stage peptide candidates through the difficult initial phases of clinical trials. As stated in CARB-X's '2024 Annual Report' from April 2025, the accelerator has supported 67% of the active Phase 1 clinical pipeline for non-traditional antibacterial therapeutics targeting critical priority pathogens. This financial backing is essential for stabilizing the developmental pipeline and ensuring that advanced peptide engineering technologies can result in commercially viable therapies that meet rigorous safety standards.

### **Market Challenge**

The Global Peptide Antibiotics Market is substantially hindered by a fragile developmental pipeline that limits the supply of late-stage therapeutics. This structural weakness arises from persistent economic difficulties within the antibiotic sector, where the high costs of complex peptide synthesis and clinical trials often outweigh potential market returns. Consequently, capital investment has declined, leading major pharmaceutical companies to reduce their participation. This environment shifts the burden of innovation to smaller biotechnology firms, which frequently lack the financial resilience needed to advance novel peptide candidates through the rigorous and

expensive stages of advanced clinical development.

This lack of investment is compounded by a critical shortage of the specialized scientific workforce needed to drive discovery in this niche field. The AMR Industry Alliance reported that in 2024, there were only approximately 3,000 researchers globally actively focused on developing new antibiotics. This scarcity of skilled human capital directly impedes the resolution of technical issues such as metabolic stability, thereby delaying the introduction of new peptide therapies and causing prolonged stagnation in market growth.

## Market Trends

Pharmaceutical companies and research institutions are increasingly utilizing AI algorithms and deep learning models to predict peptide structures, optimize amino acid sequences to lower toxicity, and accelerate the identification of novel antimicrobial peptides (AMPs). Integrating this technology enables developers to analyze immense biological datasets that are impossible to process via traditional screening methods, effectively revitalizing the early-stage discovery pipeline. Highlighting this capability, researchers recently applied machine learning to examine the proteomes of ancient organisms for hidden therapeutic candidates. In August 2025, the University of Pennsylvania reported in the article 'AI uncovers new antibiotics in ancient microbes' that their AI model successfully identified 12,623 potential antimicrobial peptides in the genomes of extinct species, demonstrating the vast volume of candidates AI can reveal.

In the manufacturing sector, there is a shift toward sustainable and automated production methods, particularly utilizing green chemistry solvents and advanced Solid-Phase Peptide Synthesis (SPPS) to reduce hazardous waste and enhance scalability. As the demand for peptide therapeutics rises, Contract Development and Manufacturing Organizations are investing heavily in automated infrastructure to bridge the gap between laboratory synthesis and commercial-scale production. Demonstrating this trend toward high-capacity automation, major industry players are significantly expanding their European facilities. For example, CordenPharma announced in a March 2025 press release titled 'CordenPharma Builds >?500m Switzerland Peptide Greenfield Site' its plans to construct a new facility featuring advanced automation with a total SPPS reactor capacity exceeding 5,000 liters.

## Key Market Players

Pfizer Inc.

Merck & Co., Inc.

AbbVie Inc

GSK Plc

Sandoz International GmbH

The Menarini Group

Novartis AG

Teva Pharmaceutical Industries Ltd.

AuroMedics Pharma LLC

## Report Scope

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type

Non-Ribosomal Synthesized Peptide Antibiotics

Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration

Injectable

Oral

Topical

Peptide Antibiotics Market, By Distribution Channel

Hospital Pharmacy

Online Pharmacy & Retail Pharmacy

## Peptide Antibiotics Market, By Region

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

## South America

Brazil

Argentina

Colombia

## Middle East & Africa

South Africa

Saudi Arabia

UAE

### **Competitive Landscape**

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

### **Available Customizations:**

Global Peptide Antibiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

### **Company Information**

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
  - 5.2.2. By Route of Administration (Injectable, Oral, Topical)
  - 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail)

Pharmacy)

5.2.4. By Region

5.2.5. By Company (2025)

5.3. Market Map

## **6. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Route of Administration

6.2.3. By Distribution Channel

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Peptide Antibiotics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type

6.3.1.2.2. By Route of Administration

6.3.1.2.3. By Distribution Channel

6.3.2. Canada Peptide Antibiotics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type

6.3.2.2.2. By Route of Administration

6.3.2.2.3. By Distribution Channel

6.3.3. Mexico Peptide Antibiotics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type

6.3.3.2.2. By Route of Administration

6.3.3.2.3. By Distribution Channel

## **7. EUROPE PEPTIDE ANTIBIOTICS MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Type
  - 7.2.2. By Route of Administration
  - 7.2.3. By Distribution Channel
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Peptide Antibiotics Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Type
      - 7.3.1.2.2. By Route of Administration
      - 7.3.1.2.3. By Distribution Channel
  - 7.3.2. France Peptide Antibiotics Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Type
      - 7.3.2.2.2. By Route of Administration
      - 7.3.2.2.3. By Distribution Channel
  - 7.3.3. United Kingdom Peptide Antibiotics Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Type
      - 7.3.3.2.2. By Route of Administration
      - 7.3.3.2.3. By Distribution Channel
  - 7.3.4. Italy Peptide Antibiotics Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Type
      - 7.3.4.2.2. By Route of Administration
      - 7.3.4.2.3. By Distribution Channel
  - 7.3.5. Spain Peptide Antibiotics Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value

- 7.3.5.2. Market Share & Forecast
  - 7.3.5.2.1. By Type
  - 7.3.5.2.2. By Route of Administration
  - 7.3.5.2.3. By Distribution Channel

## **8. ASIA PACIFIC PEPTIDE ANTIBIOTICS MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Type
  - 8.2.2. By Route of Administration
  - 8.2.3. By Distribution Channel
  - 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
  - 8.3.1. China Peptide Antibiotics Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Type
      - 8.3.1.2.2. By Route of Administration
      - 8.3.1.2.3. By Distribution Channel
  - 8.3.2. India Peptide Antibiotics Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Type
      - 8.3.2.2.2. By Route of Administration
      - 8.3.2.2.3. By Distribution Channel
  - 8.3.3. Japan Peptide Antibiotics Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Type
      - 8.3.3.2.2. By Route of Administration
      - 8.3.3.2.3. By Distribution Channel
  - 8.3.4. South Korea Peptide Antibiotics Market Outlook
    - 8.3.4.1. Market Size & Forecast
      - 8.3.4.1.1. By Value

- 8.3.4.2. Market Share & Forecast
  - 8.3.4.2.1. By Type
  - 8.3.4.2.2. By Route of Administration
  - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Peptide Antibiotics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Distribution Channel

## **9. MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Type
  - 9.2.2. By Route of Administration
  - 9.2.3. By Distribution Channel
  - 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
  - 9.3.1. Saudi Arabia Peptide Antibiotics Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Type
      - 9.3.1.2.2. By Route of Administration
      - 9.3.1.2.3. By Distribution Channel
  - 9.3.2. UAE Peptide Antibiotics Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Type
      - 9.3.2.2.2. By Route of Administration
      - 9.3.2.2.3. By Distribution Channel
  - 9.3.3. South Africa Peptide Antibiotics Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value

- 9.3.3.2. Market Share & Forecast
  - 9.3.3.2.1. By Type
  - 9.3.3.2.2. By Route of Administration
  - 9.3.3.2.3. By Distribution Channel

## **10. SOUTH AMERICA PEPTIDE ANTIBIOTICS MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Type
  - 10.2.2. By Route of Administration
  - 10.2.3. By Distribution Channel
  - 10.2.4. By Country
- 10.3. South America: Country Analysis
  - 10.3.1. Brazil Peptide Antibiotics Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Type
      - 10.3.1.2.2. By Route of Administration
      - 10.3.1.2.3. By Distribution Channel
  - 10.3.2. Colombia Peptide Antibiotics Market Outlook
    - 10.3.2.1. Market Size & Forecast
      - 10.3.2.1.1. By Value
    - 10.3.2.2. Market Share & Forecast
      - 10.3.2.2.1. By Type
      - 10.3.2.2.2. By Route of Administration
      - 10.3.2.2.3. By Distribution Channel
  - 10.3.3. Argentina Peptide Antibiotics Market Outlook
    - 10.3.3.1. Market Size & Forecast
      - 10.3.3.1.1. By Value
    - 10.3.3.2. Market Share & Forecast
      - 10.3.3.2.1. By Type
      - 10.3.3.2.2. By Route of Administration
      - 10.3.3.2.3. By Distribution Channel

## **11. MARKET DYNAMICS**

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

## **13. GLOBAL PEPTIDE ANTIBIOTICS MARKET: SWOT ANALYSIS**

## **14. PORTER'S FIVE FORCES ANALYSIS**

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

## **15. COMPETITIVE LANDSCAPE**

- 15.1. Pfizer Inc.
  - 15.1.1. Business Overview
  - 15.1.2. Products & Services
  - 15.1.3. Recent Developments
  - 15.1.4. Key Personnel
  - 15.1.5. SWOT Analysis
- 15.2. Merck & Co., Inc.
- 15.3. AbbVie Inc
- 15.4. GSK Plc
- 15.5. Sandoz International GmbH
- 15.6. The Menarini Group
- 15.7. Novartis AG
- 15.8. Teva Pharmaceutical Industries Ltd.
- 15.9. AuroMedics Pharma LLC

## **16. STRATEGIC RECOMMENDATIONS**

## **17. ABOUT US & DISCLAIMER**



## I would like to order

Product name: Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics), By Route of Administration (Injectable, Oral, Topical), By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy), By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/P0E8F528601BEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P0E8F528601BEN.html>